Greenwood Gearhart Inc. Reduces Position in Johnson & Johnson (NYSE:JNJ)

Greenwood Gearhart Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 34.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,981 shares of the company's stock after selling 2,572 shares during the quarter. Greenwood Gearhart Inc.'s holdings in Johnson & Johnson were worth $826,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Brighton Jones LLC grew its stake in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Hudson Value Partners LLC raised its holdings in Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after acquiring an additional 1,022 shares in the last quarter. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson in the 4th quarter valued at $29,000. United Services Automobile Association lifted its position in shares of Johnson & Johnson by 2.8% during the 4th quarter. United Services Automobile Association now owns 443,687 shares of the company's stock worth $64,166,000 after buying an additional 12,206 shares during the last quarter. Finally, Woodmont Investment Counsel LLC lifted its position in shares of Johnson & Johnson by 4.7% during the 4th quarter. Woodmont Investment Counsel LLC now owns 89,712 shares of the company's stock worth $12,974,000 after buying an additional 4,041 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

A number of brokerages have issued reports on JNJ. Bank of America upped their target price on Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a report on Thursday, July 17th. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Royal Bank Of Canada raised their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Barclays raised their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Finally, Benchmark raised Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and a consensus target price of $172.87.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ traded up $3.54 during midday trading on Tuesday, hitting $167.90. 9,277,637 shares of the company's stock traded hands, compared to its average volume of 8,151,378. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock has a market capitalization of $403.99 billion, a price-to-earnings ratio of 17.96, a price-to-earnings-growth ratio of 2.09 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a fifty day moving average of $154.29 and a 200 day moving average of $155.12.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 33.07% and a net margin of 25.00%. The company had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period last year, the firm earned $2.82 EPS. Johnson & Johnson's revenue for the quarter was up 5.8% compared to the same quarter last year. On average, analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.10%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.